Premium
Angiotensin converting enzyme 2 at the interface between renin‐angiotensin system inhibition and coronavirus disease 2019
Author(s) -
SiriAngkul Natthaphat,
Chattipakorn Siriporn C.,
Chattipakorn Nipon
Publication year - 2020
Publication title -
the journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.802
H-Index - 240
eISSN - 1469-7793
pISSN - 0022-3751
DOI - 10.1113/jp280138
Subject(s) - renin–angiotensin system , coronavirus , covid-19 , disease , angiotensin converting enzyme 2 , medicine , angiotensin converting enzyme , outbreak , tmprss2 , enzyme , angiotensin ii , virology , receptor , biology , infectious disease (medical specialty) , biochemistry , blood pressure
The coronavirus disease 2019 (COVID‐19) is the third major coronavirus outbreak of this century. Its aetiological agent, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), requires angiotensin converting enzyme 2 (ACE2) for cellular entry. The commonly used angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could affect SARS‐CoV‐2 infectivity and may alter COVID‐19 disease progression by altering ACE2 expression. Current evidence of ACEI/ARB‐ACE2 interaction as well as the effects of ACEIs/ARBs on viral‐associated acute lung injury is summarized and discussed in this review. This review assesses the evidence gathered so far and highlights the research that needs to be done to help inform clinical decision making.